{"id":29032,"date":"2024-08-08T11:45:22","date_gmt":"2024-08-08T06:15:22","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=29032"},"modified":"2024-08-08T11:45:25","modified_gmt":"2024-08-08T06:15:25","slug":"medtech-news-for-mimedx-docgo-labcrop","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop","title":{"rendered":"MIMEDX Launches HELIOGENTM Fibrillar Collagen Matrix; DocGo Launches Mobile X-ray Program; Labcrop\u2019s FDA De Novo Marketing Authorization; Inspire Medical Systems Receives FDA Approval; Alcyone Therapeutics Announces Continued Enrollment Approval from the FDA; Lunit\u2019s AI for Tuberculosis Detection"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a111f8b7b4df\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a111f8b7b4df\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop\/#MIMEDX_Announced_the_Launch_of_HELIOGENTM_Fibrillar_Collagen_Matrix\" >MIMEDX Announced the Launch of HELIOGENTM Fibrillar Collagen Matrix&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop\/#DocGo_Launched_Mobile_X-ray_Program_in_Partnership_with_MinXray\" >DocGo Launched Mobile X-ray Program in Partnership with MinXray<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop\/#Labcrop_Received_FDA_De_Novo_Marketing_Authorization_for_PGDx_elioTM_plasma_focus_Dx\" >Labcrop Received FDA De Novo Marketing Authorization for PGDx elioTM plasma focus Dx&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop\/#Inspire_Medical_Systems_Inc_Announced_FDA_Approval_of_the_Inspire_V_System\" >Inspire Medical Systems, Inc. Announced FDA Approval of the Inspire V System&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop\/#Alcyone_Therapeutics_Announced_Continued_Enrollment_Approval_from_the_FDA_of_the_PIERRE_Pivotal_IDE_Clinical_Study_of_the_ThecaFlex_DRXTM_System_for_Administration_of_Nusinersen\" >Alcyone Therapeutics Announced Continued Enrollment Approval from the FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRXTM System for Administration of Nusinersen<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop\/#Lunits_AI_for_Tuberculosis_Detection_Toped_in_12-Product_Comparative_Study\" >Lunit\u2019s AI for Tuberculosis Detection Toped in 12-Product Comparative Study<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-mimedx-announced-the-launch-of-heliogen-tm-fibrillar-collagen-matrix-nbsp\"><span class=\"ez-toc-section\" id=\"MIMEDX_Announced_the_Launch_of_HELIOGENTM_Fibrillar_Collagen_Matrix\"><\/span>MIMEDX Announced the Launch of HELIOGEN<sup>TM <\/sup>Fibrillar Collagen Matrix&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> July 31, 2024, <\/strong>MiMedx Group, Inc. launched HELIOGEN\u2122 Fibrillar Collagen Matrix, a particulate xenograft product designed to treat complex wounds, especially in surgical environments. HELIOGEN is a shelf-stable product that contains Type I and Type III collagen, closely resembling the natural structure of connective tissue.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201c<em>We are pleased to introduce our first xenograft option and 510(k) cleared product to complement our leading placental-based solutions in the surgical market<\/em>,\u201d stated Joseph H. Capper, MIMEDX Chief Executive Officer. \u201c<em>As we have been messaging, one of our strategic initiatives is the continued expansion of our surgical footprint, following the successful introduction of two new products designed for this care setting at the end of 2022. This initial market release of HELIOGEN represents another important step in pursuit of this objective.<\/em>\u201d<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Eric Smith, MIMEDX Senior Vice President, Marketing &amp; International, added<em>, \u201cHELIOGEN\u2014named for the product\u2019s triple helical collagen structure\u2014is an exciting addition to our portfolio and provides another tool to help our customers manage complex wounds. With a solid foundation of initial case studies and real-world evidence, we are excited for customers in various surgical settings to build on this evidence and realize improved outcomes for their patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>As per DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/skin-grafting-devices-market\"><strong>Skin Grafting Devices Market Report<\/strong><\/a><strong>\u201d,<\/strong> the global skin grafting devices market is estimated to grow at a&nbsp;<a href=\"https:\/\/www.delveinsight.com\/sample-request\/skin-grafting-devices-market\"><strong>CAGR <\/strong>of <strong>7.31%<\/strong><\/a><strong>&nbsp;<\/strong>during the forecast period from 2024 to 2030. The demand for skin grafting devices is primarily being boosted by the increasing wounds such as deep burns, skin cancer or reconstructive surgeries, skin cancer, increasing prevalence of burn injuries, leg ulcers including pressure and diabetic foot ulcers and skin infections, technological advancements in dermatomes such as the development of electric and air dermatomes, rising product launch and approvals, among others are thereby contributing to the overall growth of the skin grafting devices market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-docgo-launched-mobile-x-ray-program-in-partnership-with-minxray\"><span class=\"ez-toc-section\" id=\"DocGo_Launched_Mobile_X-ray_Program_in_Partnership_with_MinXray\"><\/span>DocGo Launched Mobile X-ray Program in Partnership with MinXray<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> August 05, 2024<\/strong>, DocGo Inc., a leading provider of technology-enabled mobile health services, announced the launch of a groundbreaking mobile X-ray program in partnership with MinXray. This program, introduced in New York City, aims to provide rapid and accessible chest X-rays for vulnerable populations, helping to identify active Tuberculosis (TB) cases.<\/p>\n\n\n\n<p>As TB cases continue to rise in cities across the US, this program serves as a timely response to an increasing public health challenge. DocGo&#8217;s mobile units, equipped with MinXray&#8217;s advanced ultra-portable, battery-powered x-ray system, provide chest x-rays for patients who test positive for TB through blood tests. The program utilizes third-party artificial intelligence technology to rapidly analyze X-ray images and prioritizes likely cases for immediate review by a board-certified radiologist. This approach ensures that individuals with active TB receive quick confirmation and appropriate referrals for further care.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cDocGo&nbsp;is on a mission to make healthcare accessible and immediate for those who need it most,\u201d<\/em> said&nbsp;Lee Beinstock, CEO of&nbsp;DocGo. <em>\u201cBy integrating our extensive mobile health infrastructure and partnering with leaders in x-ray and AI technology, we can provide timely x-ray screenings and diagnosis. We\u2019re pleased to launch this program to help reduce the spread of TB in our communities, and look forward to expanding this mobile health program for a range of diagnostic applications.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The program is designed to provide fast and efficient services, which is crucial for effectively managing and treating TB, especially among high-risk populations.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Jeanne Walter, VP of Marketing &amp; Sales at MinXray, added, <em>\u201cMinXray is committed to providing reliable and portable x-ray solutions that can be deployed anywhere, and we\u2019re pleased to partner with&nbsp;DocGo&nbsp;on this innovative program.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>In the future, DocGo plans to expand this mobile X-ray program to more locations across New York City and offer this flexible service to additional municipalities and partners. The goal is to provide X-ray diagnostics directly to patients with limited mobility and to help treat vulnerable populations.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/x-ray-devices-market\"><strong>X-ray Devices Market Report<\/strong><\/a><strong>\u201d<\/strong>, the global X-ray devices market was valued at&nbsp;<strong>USD 10.57 billion&nbsp;<\/strong>in 2023, growing at a&nbsp;<strong>CAGR<\/strong> of<strong> 8.36%<\/strong>&nbsp;during the forecast period from 2024 to 2030 to reach&nbsp;<strong>USD 17.10 billion&nbsp;<\/strong>by 2030. The demand for X-ray devices is primarily being boosted by the rising incidence observed in different types of cancer cases and rising prevalence observed in patients affected with cardiovascular diseases, rise in the number of orthopedic disorders such as injuries and diseases affecting the musculoskeletal system in humans, and technological advancements in the X-Ray devices arena which are expected to increase the product demand thereby contributing in the growth of the X-Ray devices market during the forecast period.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-labcrop-received-fda-de-novo-marketing-authorization-for-pgdx-elio-tm-plasma-focus-dx-nbsp\"><span class=\"ez-toc-section\" id=\"Labcrop_Received_FDA_De_Novo_Marketing_Authorization_for_PGDx_elioTM_plasma_focus_Dx\"><\/span>Labcrop Received FDA De Novo Marketing Authorization for PGDx elio<sup>TM <\/sup>plasma focus<sup> <\/sup>Dx&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> August 02, 2024<\/strong>, Labcorp, a global leader in laboratory services, announced that it received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for PGDx elio\u2122 plasma focus Dx. This is the first and only kitted liquid biopsy test available for pan-solid tumors in the industry.<em>&nbsp;<\/em><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe launch of PGDx elio plasma focus Dx represents a landmark expansion of&nbsp;Labcorp&#8217;s&nbsp;suite of precision oncology solutions,\u201d<\/em> said&nbsp;Shakti Ramkissoon, M.D., Ph.D., MBA, vice president, medical lead for oncology at&nbsp;Labcorp. \u201c<em>This latest liquid biopsy test offers laboratories and oncologists a convenient, cost-effective and highly targeted tumor-profiling solution that spans a wide range of solid-tumor types \u2013 particularly when tumor tissue is limited or unavailable. When paired with PGDx elio tissue complete,&nbsp;Labcorp&nbsp;now offers laboratories access to tissue and liquid genomic-profiling assays that operate on the same instrument, enabling seamless integration of these precision oncology products into routine laboratory workflows. The ability to test tissue or liquid will provide critical data and insights needed to inform more personalized treatments and care plans for patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>PGDx elio plasma focus Dx is a qualitative next-generation sequencing-based in vitro diagnostic device that employs targeted high-throughput hybridization-based capture technology. It detects single nucleotide variants (SNVs), insertions and deletions (indels) in 33 genes, copy number amplifications (CNAs) in five genes, and translocations in three genes. The assay focuses on guideline-recommended biomarkers to provide more accurate clinical assessments and is paired with automated bioinformatics for faster results. This solution enhances oncologists&#8217; ability to make timely treatment decisions when combined with other laboratory and clinical findings and also supports sample and data ownership.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/biopsy-devices-market\"><strong>Biopsy Devices Market Report<\/strong><\/a><strong>\u201d,<\/strong> the&nbsp;global biopsy devices market&nbsp;is anticipated to grow at a <strong>CAGR <\/strong>of<strong> 5.1%<\/strong> during the forecast&nbsp;period from 2024 to 2030. The&nbsp;biopsy device&nbsp;market&nbsp;is witnessing positive growth owing to various factors such as the increasing prevalence of breast cancer, the rise in the geriatric population, the rising incidence of lung cancer, and rising technological advancements to the product offerings. Therefore, the market for biopsy devices is estimated to grow during the&nbsp;biopsy devices market forecast&nbsp;period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-inspire-medical-systems-inc-announced-fda-approval-of-the-inspire-v-system-nbsp\"><span class=\"ez-toc-section\" id=\"Inspire_Medical_Systems_Inc_Announced_FDA_Approval_of_the_Inspire_V_System\"><\/span>Inspire Medical Systems, Inc. Announced FDA Approval of the Inspire V System&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> August 02, 2024, <\/strong>Inspire Medical Systems, Inc., a medical technology company specializing in innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced that the FDA approved the Inspire V therapy system. This system includes the next-generation neurostimulator, along with a Bluetooth\u00ae patient remote and physician programmer.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are thrilled to announce the FDA approval of our next-generation Inspire neurostimulation system,\u201d <\/em>said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems.<em> \u201cThe FDA approval marks a key milestone for the future of Inspire therapy and reinforces the many years of hard work by our team members.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The company is concentrating on operational readiness, which involves product manufacturing and building inventory levels to support a comprehensive commercial launch in the United States. They are planning for a soft launch in late 2024, followed by a full launch in 2025.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/neurostimulation-devices-market\"><strong>Neurostimulation Devices Market Report<\/strong><\/a><strong>\u201d,<\/strong> the neurostimulation devices market was valued at&nbsp;<strong>USD 5.82 billion in 2023<\/strong>, growing at a<strong>&nbsp;CAGR <\/strong>of <strong>11.77%<\/strong>&nbsp;during the forecast period from&nbsp;2024 to 2030,&nbsp;to reach&nbsp;<strong>USD 11.34 billion<\/strong>&nbsp;by&nbsp;<strong>2030<\/strong>. The market for neurostimulator devices is experiencing significant growth, driven by several key factors. The rising incidence of chronic diseases, such as migraine, headaches, and epilepsy, has created a greater demand for effective treatment options, leading to increased use of neurostimulators. Additionally, the prevalence of lifestyle-related diseases like depression and chronic pain has surged, further boosting the need for these devices as they offer promising solutions for managing these conditions. Technological advancements in neurostimulator devices have also played a crucial role, with regulatory bodies across the globe approving a growing number of innovative and advanced products. This regulatory support has facilitated the widespread adoption of neurostimulators, enhancing their market growth. Collectively, the increasing incidence of chronic and lifestyle diseases, along with the adoption of advanced, approved neurostimulator devices, is driving the expansion of this market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-alcyone-therapeutics-announced-continued-enrollment-approval-from-the-fda-of-the-pierre-pivotal-ide-clinical-study-of-the-thecaflex-drx-tm-system-for-administration-of-nusinersen\"><span class=\"ez-toc-section\" id=\"Alcyone_Therapeutics_Announced_Continued_Enrollment_Approval_from_the_FDA_of_the_PIERRE_Pivotal_IDE_Clinical_Study_of_the_ThecaFlex_DRXTM_System_for_Administration_of_Nusinersen\"><\/span>Alcyone Therapeutics Announced Continued Enrollment Approval from the FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRX<sup>TM <\/sup>System for Administration of Nusinersen<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> July 31, 2024<\/strong>, Alcyone Therapeutics Inc. (Alcyone), a clinical-stage biotechnology company at the forefront of next-generation precision genetic therapies and delivery solutions for complex neurological conditions, announced that the U.S. Food and Drug Administration (FDA) had approved the continuation of enrollment for the PIERRE study. This study aims to assess the safety and effectiveness of the ThecaFlex DRx\u2122 subcutaneous port and intrathecal catheter system for chronic intrathecal access, CSF aspiration, and the delivery of SPINRAZA\u00ae (nusinersen) in SMA patients, offering an alternative to repeat lumbar punctures.<\/p>\n\n\n\n<p>As previously announced, the PIERRE IDE trial was designed to enroll up to 90 SMA patients, aged 3 years and older, and was conducted in two stages. The first stage, which involved enrolling and implanting 10 SMA patients, administering nusinersen, and monitoring them for 30 days, had been completed. During this stage, all attempts to aspirate and infuse through the ThecaFlex port were successful, with no infections or device-related adverse events reported. Following a review of the data from this initial stage, the FDA approved the continuation of the trial, allowing the enrollment of an additional 80 SMA patients across up to 30 centers in the U.S. and Europe.<\/p>\n\n\n\n<p>From the experience with the first 10 SMA patients in the trial, the implantation of ThecaFlex took between one and two hours, depending on the patient&#8217;s spinal complexity. Most SMA patients were discharged from the hospital within 24 hours of implantation. After implantation, the infusion procedure was usually carried out in a standard exam room rather than a specialized setting. The entire infusion procedure lasted less than 30 minutes, with the actual nusinersen subcutaneous infusion taking under 10 minutes.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201c<em>As we approach the next stage of the PIERRE IDE study, we will continue to evaluate the safety and efficacy of the ThecaFlex system to help patients with spinal muscular atrophy receive the SPINRAZA\u00ae (nusinersen) therapy<\/em>,\u201d said Dr. Scellig Stone, M.D., Ph.D., FRCSC the Boston Children\u2019s Hospital primary investigator for the PIERRE study. \u201c<em>The initial data and patient feedback are optimistic and a key first step toward developing a less invasive, more accessible procedure that may improve the overall dosing experience for SMA patients and may help optimize hospital resources<\/em>.\u201d<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe were pleased to receive the recommendation from the independent data monitoring safety committee to continue enrollment without any changes to the PIERRE study protocol as well as the FDA\u2019s subsequent approval to continue enrollment,\u201d <\/em>said Dr. Kathrin Meyer, Ph.D., Alcyone\u2019s Chief Scientific Officer and Head of Research &amp; Development<em>. \u201cThis represents a tangible step toward our goal of substantially improving treatment experience for patients requiring repeat intrathecal delivery of medications for the treatment of neurological disorders.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The PIERRE study is currently evaluating the potential clinical benefits of the ThecaFlex DRx System, which may include: (a) facilitating routine subcutaneous administration of ASO (antisense oligonucleotide) therapies to the cerebrospinal fluid, and (b) decreasing the need for anesthesia and radiation exposure compared to repeated lumbar punctures for SPINRAZA infusion in SMA patients.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cFor those who currently require anesthesia and radiographic guidance for delivery of nusinersen, which exposes them to radiation, ThecaFlex could shift administration from a specialized visit to an exam room setting,\u201d <\/em>said Dr. Michael Muhonen, M.D. at the Children\u2019s Hospital of Orange County in California<em>. \u201cI look forward to the continued enrollment of the study and future learnings from the patient therapy administration experience with this innovative device.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chest-drainage-catheters-market\"><strong>Chest Drainage Catheters Market Report<\/strong><\/a><strong>\u201d<\/strong>, the global chest drainage catheters market is estimated to grow at a&nbsp;<strong>CAGR <\/strong>of<strong> 4.78%<\/strong>&nbsp;during the forecast period from 2024 to 2030. The demand for chest drainage catheters is primarily being boosted by the increasing patient population suffering from various cardiovascular diseases (CVDs) requiring surgeries, the increasing burden of spontaneous pneumothorax, the growing preference for minimally-invasive surgeries, continuous innovation in product development, and others, thereby contributing to the overall growth of the chest drainage catheters market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lunit-s-ai-for-tuberculosis-detection-toped-in-12-product-comparative-study\"><span class=\"ez-toc-section\" id=\"Lunits_AI_for_Tuberculosis_Detection_Toped_in_12-Product_Comparative_Study\"><\/span>Lunit\u2019s AI for Tuberculosis Detection Toped in 12-Product Comparative Study<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> August 06, 2024, <\/strong>Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced that its AI-powered chest X-ray analysis software, Lunit INSIGHT CXR, had shown superior performance in detecting tuberculosis (TB) in a large-scale, independent study published in The Lancet Digital Health.<\/p>\n\n\n\n<p>Despite being a curable disease, tuberculosis (TB) remains the world&#8217;s second leading cause of death from a single infectious agent, with an estimated 10.6 million new cases reported in 2022. A significant challenge in controlling TB is underdiagnosis, with 3.1 million cases remaining undetected that year. Although chest X-rays are more sensitive than symptom screening, their effectiveness is often hindered by variability in human interpretation and a shortage of radiologists in high-burden countries. This situation highlights the crucial need for advanced AI assistance.<\/p>\n\n\n\n<p>The study, led by Dr. Zhi Zhen Qin and a research team from the Stop TB Partnership at UNOPS and Heidelberg University Hospital, assessed 12 commercially available AI products for TB detection using data from South Africa&#8217;s national TB prevalence survey. Lunit INSIGHT CXR achieved the highest area under the receiver operating characteristic curve (AUC) at 0.902, significantly outperforming the other products.<\/p>\n\n\n\n<p>Key findings for Lunit INSIGHT CXR include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The highest AUC (0.902) among all tested products.<\/li>\n\n\n\n<li>89.9% sensitivity at 67.7% specificity, aligning with the WHO target product profile.<\/li>\n\n\n\n<li>89.5% sensitivity at 70.2% specificity, also meeting the WHO target product profile.<\/li>\n\n\n\n<li>Consistent high sensitivity (&gt;90%) across a broad range of thresholds.<\/li>\n<\/ul>\n\n\n\n<p>The study, which included 774 participants (258 bacteriologically confirmed TB cases), is the first to comprehensively evaluate multiple AI products in a high TB setting.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis landmark study not only showcases our AI&#8217;s superior accuracy but also demonstrates its alignment with WHO standards,\u201d<\/em> said&nbsp;Brandon Suh, CEO of Lunit. <em>\u201cLunit INSIGHT CXR&#8217;s ability to maintain high sensitivity across diverse populations and thresholds is particularly crucial in resource-limited settings, where every undetected case can have far-reaching consequences. By bridging the gap in TB diagnosis, we are contributing to a future where no case goes undetected, especially in regions where it matters most.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The study&#8217;s findings have important implications for TB screening in high-burden areas. Lunit INSIGHT CXR&#8217;s strong performance, especially its ability to maintain high sensitivity across various thresholds, supports the development of customized screening strategies. This flexibility allows healthcare systems to enhance detection rates while efficiently managing resources for confirmatory testing, potentially making TB programs more accessible and cost-effective across different healthcare settings.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/tuberculosis-diagnostics-market\"><strong>Tuberculosis Diagnostics Market Report<\/strong><\/a><strong>\u201d,<\/strong> the global tuberculosis diagnostics market is estimated to grow at a&nbsp;<a href=\"https:\/\/www.delveinsight.com\/sample-request\/tuberculosis-diagnostics-market\"><strong>CAGR <\/strong>of<strong> 5.11%<\/strong><\/a>&nbsp;during the forecast period from 2024 to 2030. The demand for tuberculosis diagnostics is primarily being boosted by the increasing prevalence of tuberculosis and multidrug-resistant tuberculosis (MDR-TB). Moreover, the availability of technologically advanced Point-of-Care (POC) diagnostic methods, increasing awareness about early diagnosis, increasing product launches and approvals, and innovation in product development among others, thereby contribute to the overall growth of the tuberculosis diagnostics market during the forecast period from 2024 to 2030.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MIMEDX Announced the Launch of HELIOGENTM Fibrillar Collagen Matrix&nbsp; On July 31, 2024, MiMedx Group, Inc. launched HELIOGEN\u2122 Fibrillar Collagen Matrix, a particulate xenograft product designed to treat complex wounds, especially in surgical environments. HELIOGEN is a shelf-stable product that contains Type I and Type III collagen, closely resembling the natural structure of connective tissue. [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":29035,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19875,19874,22221,704,2753,17021,16975,19143,19351,22220,22222,19626,19225],"industry":[17226],"therapeutic_areas":[17242,17231,17245],"class_list":["post-29032","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biopsy-devices","tag-biopsy-devices-market","tag-chest-drainage-catheters","tag-fda","tag-medical-device","tag-medical-devices-market","tag-medtech-market","tag-neurostimulation-devices","tag-neurostimulation-devices-market","tag-skin-grafting-devices","tag-tuberculosis-diagnostics","tag-x-ray-devices","tag-x-ray-devices-market","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-infectious-diseases","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | MIMEDX, DocGo, Labcrop<\/title>\n<meta name=\"description\" content=\"MIMEDX\u2019s HELIOGENTM Fibrillar Collagen Matrix; DocGo\u2019s Mobile X-ray Program; Inspire Medical Systems\u2019 Inspire V System\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | MIMEDX, DocGo, Labcrop\" \/>\n<meta property=\"og:description\" content=\"MIMEDX\u2019s HELIOGENTM Fibrillar Collagen Matrix; DocGo\u2019s Mobile X-ray Program; Inspire Medical Systems\u2019 Inspire V System\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-08T06:15:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-08T06:15:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/08114504\/medtech-news-for-mimedx-docgo-labcrop.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | MIMEDX, DocGo, Labcrop","description":"MIMEDX\u2019s HELIOGENTM Fibrillar Collagen Matrix; DocGo\u2019s Mobile X-ray Program; Inspire Medical Systems\u2019 Inspire V System","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop","og_locale":"en_US","og_type":"article","og_title":"MedTech News | MIMEDX, DocGo, Labcrop","og_description":"MIMEDX\u2019s HELIOGENTM Fibrillar Collagen Matrix; DocGo\u2019s Mobile X-ray Program; Inspire Medical Systems\u2019 Inspire V System","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-08-08T06:15:22+00:00","article_modified_time":"2024-08-08T06:15:25+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/08114504\/medtech-news-for-mimedx-docgo-labcrop.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop","name":"MedTech News | MIMEDX, DocGo, Labcrop","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/08114504\/medtech-news-for-mimedx-docgo-labcrop.png","datePublished":"2024-08-08T06:15:22+00:00","dateModified":"2024-08-08T06:15:25+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"MIMEDX\u2019s HELIOGENTM Fibrillar Collagen Matrix; DocGo\u2019s Mobile X-ray Program; Inspire Medical Systems\u2019 Inspire V System","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-mimedx-docgo-labcrop#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/08114504\/medtech-news-for-mimedx-docgo-labcrop.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/08114504\/medtech-news-for-mimedx-docgo-labcrop.png","width":772,"height":482,"caption":"medtech-news-for-mimedx-docgo-labcrop"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/08114504\/medtech-news-for-mimedx-docgo-labcrop-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biopsy Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biopsy Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chest Drainage Catheters<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurostimulation Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurostimulation Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Skin Grafting Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tuberculosis Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">X-Ray Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">X-Ray Devices Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biopsy Devices<\/span>","<span class=\"advgb-post-tax-term\">Biopsy Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Chest Drainage Catheters<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Neurostimulation Devices<\/span>","<span class=\"advgb-post-tax-term\">Neurostimulation Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Skin Grafting Devices<\/span>","<span class=\"advgb-post-tax-term\">Tuberculosis Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">X-Ray Devices<\/span>","<span class=\"advgb-post-tax-term\">X-Ray Devices Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Aug 8, 2024","modified":"Updated on Aug 8, 2024"},"absolute_dates_time":{"created":"Posted on Aug 8, 2024 11:45 am","modified":"Updated on Aug 8, 2024 11:45 am"},"featured_img_caption":"medtech-news-for-mimedx-docgo-labcrop","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=29032"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29032\/revisions"}],"predecessor-version":[{"id":29033,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29032\/revisions\/29033"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/29035"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=29032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=29032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=29032"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=29032"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=29032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}